CCI-779 rapamycin derivative targeting the FRAP/mTOR kinase regulatory update

The FDA granted Fast Track designation to AHP subsidiary Wyeth-Ayerst for its CCI-779 mTOR ( mammalian target of rapamycin) inhibitor to treat renal cell carcinoma refractory to interleukin-2 (IL-2)....